224 withdrawn. 224 Phase 1, 80 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 224 | Withdrawn 224 |
| Phase 2 | 80 | Withdrawn 80 |
Follow Infections: new trials by email Literature Review of Infections trials Research Report on Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Immunogenicity of VPM1002 Vaccination or BCG Revaccination Against TB in Pre-Adolescents Living With and Without HIV in South Africa VPM1002 Vaccine, BCG Vaccine, Placebo - Tuberculosis, HIV Infections | Phase 1 / Phase 2 | Withdrawn | International Maternal Pediatric Adolescent AIDS Clinical Trials Group | 2026-12-31 | 2026-08-17 | |
| Genitourinary Study of Fostering Lactobacillus to Optimize the Microbiome in Women's Health (GUD-FLORA) Lactobacillus crispatus probiotic - Recurrent UTIs | Phase 1 | Withdrawn | Duke University | 2026-12-01 | 2026-08-28 | |
| Pre-emptive Anakinra for Cytokine Event Reduction Anakinra (Kineret®) - B-Acute Lymphoblastic Leukemia, CAR-T Cell Therapy | Phase 1 / Phase 2 | Withdrawn | Kevin McNerney | 2026-10-01 | 2026-08-13 | |
| Safety Evaluation of PfSPZ Vaccine in Pregnant Women in Mali (MalVIP1) PfSPZ Vaccine, PfSPZ Diluent, Normal Saline - Malaria | Phase 1 | Withdrawn | National Institute of Allergy and Infectious Diseases (NIAID) | 2026-09-14 | 2026-09-16 | |
| H1ssF Flu Vaccine Clinical Trial H1ssF vaccine, Flucelvax seasonal vaccine - Influenza | Phase 1 | Withdrawn | University of Minnesota | 2026-08-01 | 2026-09-21 | |
| A Study to Evaluate the Intratumoral Influenza Vaccine Administration in Patients With Breast Cancer Fluzone Quadrivalent - Breast Cancer, Breast Cancer Triple Negative | Phase 1 | Withdrawn | Rush University Medical Center | 2026-06-01 | 2026-03-11 | |
| Use of hUC-MSC Product (BX-U001) for the Treatment of COVID-19 With ARDS Human umbilical cord mesenchymal stem cells + best supportive care, Placebo control + best supportive care - COVID-19, ARDS | Phase 1 / Phase 2 | Withdrawn | Baylx Inc. | 2026-06-01 | 2025-12-29 | |
| Ceftriaxone for Post-Treatment Lyme Disease Ceftriaxone treatment, Placebo - Post-Treatment Lyme Disease Syndrome | Phase 1 / Phase 2 | Withdrawn | Hackensack Meridian Health | 2026-05-14 | 2026-05-18 | |
| A Phase 1 Study of Cizutamig in IgE Mediated Diseases Cizutamig - IgE-Mediated Hypersensitivity, IgE Mediated Food Allergy | Phase 1 | Withdrawn | Candid Therapeutics | 2026-04-01 | 2026-07-22 | |
| A Challenge Study to Assess the Blood-stage Efficacy of Full-length SUM-101 Malaria Vaccine Candidate SUM-101, CHMI, Verorab® - Malaria Fever | Phase 1 | Withdrawn | European Vaccine Initiative | 2026-03-20 | 2026-09-11 | |
| Safety and Challenge Study of BCG TICE(R) Vaccination to Test Tuberculosis Immunity in Heathy Humans BCG TICE strain, Sodium Chloride, 0.9%, Sterile Water for Injection - Tuberculosis | Phase 1 | Withdrawn | National Institute of Allergy and Infectious Diseases (NIAID) | 2025-11-26 | 2025-12-17 | |
| Safety and Immunogenicity Study of SCB-1019T in Children low dose SCB-1019T, adjuvanted low dose SCB-1019T, high dose SCB-1019T - RSV Infection | Phase 1 | Withdrawn | Clover Biopharmaceuticals AUS Pty | 2025-10-01 | 2024-12-31 | |
| A Study on 2 Different Combination Tablets of Nirmatrelvir Plus Ritonavir to Compare Them With Marketed Paxlovid in Healthy Participants Paxlovid, Nirmatrelvir/ritonavir - Biological Availability, Healthy Participants | Phase 1 | Withdrawn | Pfizer | 2025-08-15 | 2025-12-26 | |
| A Study of HY004 Treatment in Adult Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r B-ALL) HY004, Cyclophosphamide, Fludarabine Phosphate - B-cell Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Withdrawn | Juventas Cell Therapy Ltd. | 2025-06-30 | 2025-08-08 | |
| A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Systemic Lupus Erythematosus ATA3219 - Lupus Nephritis, Systemic Lupus Erythematosus | Phase 1 | Withdrawn | Atara Biotherapeutics | 2025-04-16 | 2025-04-24 | |
| Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy Interferon Beta-1A, X-Ray Imaging, Echocardiography - Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Withdrawn | Fred Hutchinson Cancer Center | 2025-04-01 | 2024-07-12 | |
| Pharmacokinetics Safety and Acceptability of DRV/r for Children Living With HIV DRV/r FDC (120/20mg) - HIV Infections | Phase 1 / Phase 2 | Withdrawn | PENTA Foundation | 2025-02-01 | 2026-03-05 | |
| Immune Reconstitution Monitoring and Pneumococcal Vaccination in Patients Treated With CAR-T Cells Commercial CAR-T, Investigational CAR-T - Malignancy, Cancer | Phase 1 / Phase 2 | Withdrawn | UNC Lineberger Comprehensive Cancer Center | 2025-01-20 | 2026-01-06 | |
| A Study to Learn About Bivalent COVID-19 RNA Vaccine Candidate(s) in Healthy Infants and Children Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose, Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 6 microgram dose, Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 10 microgram dose - COVID-19 | Phase 1 | Withdrawn | BioNTech SE | 2025-01-06 | 2024-03-18 | |
| ExoFlo™ Infusion for Post-Acute COVID-19 and Chronic Post-COVID-19 Syndrome Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles, Saline - Covid19, Postviral Syndrome | Phase 1 / Phase 2 | Withdrawn | Direct Biologics, LLC | 2024-11-01 | 2024-11-22 |
Showing 20 of 224. Sign in to see all of them.
COVID-19 (52) · HIV Infections (32) · Burkitt Lymphoma (22) · Influenza, Human (13) · Lymphoma (12) · Leukemia (10) · Leukemia, Lymphocytic, Chronic, B-Cell (10) · Lymphoma, Non-Hodgkin (10) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (10) · Acquired Immunodeficiency Syndrome (9) · Lymphoma, Mantle-Cell (9) · Coronavirus Infections (8) · Leukemia, Myeloid, Acute (8) · Lymphoma, B-Cell, Marginal Zone (8)
Virus Diseases (162) · RNA Virus Infections (126) · Respiratory Tract Diseases (77) · Respiratory Tract Infections (76) · Immune System Diseases (67) · Lung Diseases (59) · Coronaviridae Infections (56) · Nidovirales Infections (56) · Pneumonia (51) · Pneumonia, Viral (51) · Blood-Borne Infections (49) · Communicable Diseases (49) · Coronavirus Infections (48) · Urogenital Diseases (47)
Cyclophosphamide (6) · Sodium Chloride (6) · fludarabine phosphate (6) · Injections (5) · Saline Solution (4) · Aluminum Hydroxide (3) · Blood Specimen Collection (3) · Moxifloxacin (3) · STI-2020 (3) · fludarabine (3) · 3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide (2) · ALT-803 (2) · Anti-Bacterial Agents (2) · Azithromycin (2) · BCG Vaccine (2)
National Institute of Allergy and Infectious Diseases (NIAID) (32) · GlaxoSmithKline (6) · M.D. Anderson Cancer Center (4) · AM-Pharma (3) · ImmunityBio, Inc. (3) · Massachusetts General Hospital (3) · Merck Sharp & Dohme LLC (3) · Sorrento Therapeutics, Inc. (3) · Stanford University (3) · ViiV Healthcare (3) · AlloVir (2) · Bristol-Myers Squibb (2) · Children's Oncology Group (2) · Duke University (2) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (2)
United States (79) · Australia (7) · China (7) · Canada (6) · Netherlands (5) · United Kingdom (5) · Germany (3) · Austria (2) · Belgium (2) · Brazil (2) · India (2) · Israel (2) · South Korea (2) · Spain (2) · Taiwan (2)
Mike Royal, MD (3) · Kevin V Grimes, MD (2) · Lorenzo Berra, MD (2) · Michael Keefer (2) · Professor P.E. Verweij, MD, PhD (2) · Richard T Davey, M.D. (2) · Swati Naik, MD (2) · Abdullah M Al-Osaimi, MD (1) · Adrian S Wagg, MD (1) · Aili He, MD, PhD (1) · Alan Bocking, MD, FRCSC (1)
PMID 34473343, PMID 11401954, PMID 15374844, PMID 19641203, PMID 21956689, PMID 26794905, PMID 34074163, PMID 35313959, PMID 8615453, PMID 9364715, PMID 9840607
2017 (2), 2019 (2), 2014 (1), 5UM1AI148684-03 (1), K12TR005104 (1), N01AI30025 (1), P30CA015083 (1), P30CA015704 (1), P30CA016672 (1), P30CA022453 (1), R01HL130763 (1), U10CA180886 (1), U10HD047905 (1), U19AI051915 (1), UM1AI068616 (1)